Epidemiological, Clinicopathological and Prognosis Features of Moroccan Patients with Nasopharyngeal Carcinoma.
Clinicopathology
Nasopharyngeal carcinoma
prognostic
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 May 2023
01 May 2023
Historique:
received:
15
03
2022
medline:
31
5
2023
pubmed:
29
5
2023
entrez:
29
5
2023
Statut:
epublish
Résumé
A distinct epidemiology, etiology, clinical characteristics, and therapeutic outcomes characterize nasopharyngeal carcinoma (NPC) from other head and neck cancers. An actualized analysis of NPC patients' features enables a global view of NPC management. Accordingly, the current study investigated the epidemiological and clinical characteristics of Moroccan patients with NPC, as well as their 4-years survival outcomes and influencing prognostic factors. We prospectively analyzed data of 142 histologically confirmed Moroccan patients with NPC between October 2016 and February 2019. Kaplan-Meier and Cox regression analyses were used to assess predictive prognostic factors related to NPC. All analyses were conducted using SPSS version 21 statistical software. In the present study, a net male predominance was found, with a mean age of 44±16.3 years old. Advanced stages of NPC were observed in 64.1% of patients, and 32.4% of patients presented with distant metastasis at diagnosis. The 4-years overall survival, locoregional relapse-free survival, distant metastasis-free survival and progression-free survival were 68.0%, 63.0%, 53.9%, and 39.9%, respectively. Age, N category and distant metastasis were identified as the most important independent prognosis factors for NPC in this cohort (p<0.05). In conclusion, NPC affects young adults and is frequently diagnosed at advanced disease stages, impacting therefore negatively patients survival; which is in line with data from endemic areas for NPC. The current study clearly highlights that a greater attention should be directed to improving the management of this aggressive malignancy.
Identifiants
pubmed: 37247266
doi: 10.31557/APJCP.2023.24.5.1477
pmc: PMC10495879
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1477-1486Références
Chin J Cancer. 2016 May 05;35:41
pubmed: 27146632
Chin J Cancer. 2015 May 14;34(8):350-7
pubmed: 26058679
BMC Cancer. 2013 May 04;13:226
pubmed: 23642234
Cancer Med. 2020 Sep;9(17):6147-6158
pubmed: 32649056
Sci Rep. 2016 Jan 18;6:19290
pubmed: 26776301
Viruses. 2022 Dec 25;15(1):
pubmed: 36680107
Rev Med Liege. 2019 May;74(5-6):349-353
pubmed: 31206279
Lancet. 2005 Jun 11-17;365(9476):2041-54
pubmed: 15950718
J Oncol. 2019 Nov 29;2019:4094395
pubmed: 31871457
Int J Cancer. 2000 Feb 1;85(3):364-9
pubmed: 10652428
Osong Public Health Res Perspect. 2016 Dec;7(6):360-372
pubmed: 28053841
Eur J Cancer. 2003 Jul;39(11):1535-41
pubmed: 12855259
Cancer Metastasis Rev. 2017 Sep;36(3):411-423
pubmed: 28801840
Cancer Causes Control. 2015 Jun;26(6):913-21
pubmed: 25822573
Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1035-1047
pubmed: 33849968
CA Cancer J Clin. 2016 Jul;66(4):337-50
pubmed: 26891458
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Otolaryngol Head Neck Surg. 2016 Aug;155(2):274-80
pubmed: 27143706
Chin J Cancer. 2010 Feb;29(2):145-50
pubmed: 20109341
Anticancer Drugs. 2015 Nov;26(10):1017-25
pubmed: 26241803
J Radiat Res. 2000 Oct;41 Suppl:53-62
pubmed: 11142212
Semin Cancer Biol. 2012 Apr;22(2):96-106
pubmed: 22313875
Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1107-16
pubmed: 15752890
Ann Nucl Med. 2022 Oct;36(10):876-886
pubmed: 35836088
Semin Cancer Biol. 2012 Apr;22(2):117-26
pubmed: 22311401
Int J Biol Sci. 2018 Apr 5;14(5):549-556
pubmed: 29805306
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765-77
pubmed: 17035381
Radiat Oncol. 2014 Dec 05;9:274
pubmed: 25477058
Eur J Med Chem. 2020 Dec 1;207:112758
pubmed: 32858472
Saudi Med J. 2004 Nov;25(11):1579-82
pubmed: 15573182
Chin Clin Oncol. 2016 Apr;5(2):16
pubmed: 27121876
Eur J Cancer. 2003 Nov;39(16):2349-54
pubmed: 14556927
Lancet Oncol. 2015 Jun;16(6):645-55
pubmed: 25957714
Malays J Med Sci. 2009 Oct;16(4):50-4
pubmed: 22135512
Semin Radiat Oncol. 2012 Jul;22(3):233-44
pubmed: 22687948
Br J Cancer. 2013 Aug 6;109(3):788-94
pubmed: 23807164
Infect Agent Cancer. 2021 Feb 18;16(1):15
pubmed: 33602309
Ann Transl Med. 2019 Dec;7(23):768
pubmed: 32042784
PLoS One. 2015 May 12;10(5):e0126108
pubmed: 25965270
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2285-94
pubmed: 24252872
Ann Oncol. 2021 Apr;32(4):452-465
pubmed: 33358989
Eur J Cancer. 2013 Jan;49(1):150-5
pubmed: 22892061
Eur J Cancer. 2003 Oct;39(15):2121-35
pubmed: 14522369
Oncotarget. 2015 Sep 15;6(27):24511-21
pubmed: 26087194
Am J Epidemiol. 2013 Aug 1;178(3):325-38
pubmed: 23785114
Oncotarget. 2017 Oct 24;8(57):97323-97330
pubmed: 29228613
BMC Cancer. 2015 Nov 16;15:906
pubmed: 26573573